# CRYO-CELL INTERNATIONAL, INC. (CCEL) · Edgar & Edgarette company card

> Cryo-Cell International (CCEL) saw revenue fall 1.3% in FY2025 to $32 million, operating margin 1.5%, in line with the 2.0% median for misc health & allied services, equity -30.1% of assets, and its dividend per share fell in the latest year on record. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 862692 · fiscal year ended 2025-11-30 · 5 audited years read · [page](https://www.pops4.com/boards/company/CCEL) · [JSON](https://www.pops4.com/boards/company/CCEL.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $32M |
| Revenue growth, 1 year | -1.3% |
| Revenue growth per year | 2.2% |
| Operating margin | 1.5% (prior year 10.9%) |
| Net margin | -7.7% |
| Operating cash flow | $5M |
| Capital spending | $230,475 |
| Free cash flow | $5M |
| Cash | $319,031 |
| Long-term debt | $8M |
| Total assets | $62M |
| Total equity | −$19M |
| Equity ÷ assets | -30.1% |
| Return on equity | — |
| Dividend per share | $0.25 |
| Dividend years rising | 0 |

## Readings, computed from those figures

- Altman Z: -3.07 (distress zone)
- Piotroski F: 6 of 9 (solid)
- Beneish M: -3.18 (below the −1.78 line)
- Health Harbor boat: Weathered boat · two warning signs · liabilities exceed assets (often from years of share buybacks, not always distress); revenue is hard to predict: its 80% range is ±35%
- Cash Compass: Steady earner · steady and paying a dividend, with average cash

## Edgarette's reading

Exposure: revenue $31.6M (FY2025), total debt $8.4M. Experience: revenue down 1.3% on the year, up 2.2% a year over 4 years; operating margin 1.5%, down from 10.9%. Soundness: equity -30.1% of assets (liabilities exceed assets), the dividend per share fell in the latest year on record. Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $21.4M and $44.5M next year (method v4.1: its own 6-year record of growth weighed at 63% against under $50M filers; across 2019–2025, 69.0% landed inside, 83.4% on the one year the method never saw). In a shock year the stress range is $20.4M to $46.9M. A statistical range, not company guidance. Against peers (54 filers, $50M+ revenue, its industry group): operating margin 1.5% against a 2.0% median; growth -1.3% against 13.0%.

Range logged 2026-10-14, receipt d3d62e2d87fe84ae, status open. A statistical range, not company guidance.

## Health Watch, last 12 months

- Item 3.01 Exchange listing notice or transfer: 2, latest 2026-05-08 ([filing](https://www.sec.gov/Archives/edgar/data/862692/000119312526214569/0001193125-26-214569-index.htm))

## Recent filings

- 8-K · filed 2026-10-28 · 5.07 Submission of Matters to a Vote of Security Holders · [filing](https://www.sec.gov/Archives/edgar/data/862692/000119312526436296/0001193125-26-436296-index.htm)
- DEF 14A · filed 2026-10-13 · [filing](https://www.sec.gov/Archives/edgar/data/862692/000119312526420608/0001193125-26-420608-index.htm)
- 10-Q · filed 2026-10-09 · [filing](https://www.sec.gov/Archives/edgar/data/862692/000119312526419156/0001193125-26-419156-index.htm)
- 8-K · filed 2026-09-14 · 8.01 Other Events · [filing](https://www.sec.gov/Archives/edgar/data/862692/000119312526390647/0001193125-26-390647-index.htm)
- 10-Q · filed 2026-07-15 · [filing](https://www.sec.gov/Archives/edgar/data/862692/000119312526304834/0001193125-26-304834-index.htm)
- 8-K · filed 2026-05-08 · 3.01 Notice of Delisting or Failure to Satisfy a Listing Rule; 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/862692/000119312526214569/0001193125-26-214569-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0000862692.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=862692

## Cite

POPS4, Edgar & Edgarette: CRYO-CELL INTERNATIONAL, INC. (CCEL) company card, from the company's own SEC filings, accessed 2026-11-21, https://www.pops4.com/boards/company/CCEL. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.

